Name: Tumor necrosis factor (TNF) - BioCentury Target Profiles - BCIQ
Creator: Biocentury

Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

Company Profiles
Target Profiles
Product Profiles

Explore BCIQ profiles by entering a target name.

REQUEST A FREE TRIAL

BioCentury | Mar 29, 2025

Product Development

Bispecifics for I&I: Bypassing combination complexity

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases

BioCentury | Mar 19, 2025

Emerging Company Profile

Trio: Introducing two new types of dual-targeting antibodies for cancer

San Francisco Bay Area biotech has two antibody platforms designed to improve on the potency and safety of bispecifics

BioCentury | Mar 12, 2025

Product Development

Autoimmune CAR T companies compete for resources

Crowding in the autoimmune CAR T field brings recruitment challenges

BioCentury | Feb 28, 2025

Product Development

Caribou: Solving the allogeneic problem with CRISPR

Caribou selected a de-risked target and modality to take on multiplexed editing

BioCentury | Feb 25, 2025

Emerging Company Profile

Lifordi: Applying ADCs to autoimmune conditions

With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing

BioCentury | Feb 25, 2025

Product Development